Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 4/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4088960 | 1.00 | OPRD1 (0.44) | OPRD1KCNA5KCNH2HRH3MEN1 | |
| SCHEMBL4975855 | 1.00 | OPRD1 (0.44) | OPRD1KCNA5KCNH2HRH3MEN1 | |
| SCHEMBL4094666 | 0.84 | HRH3 (0.42) | OPRD1KCNA5KCNH2HRH3MEN1 | |
| SCHEMBL4099833 | 0.84 | HRH3 (0.42) | OPRD1KCNA5KCNH2HRH3MEN1 | |
| SCHEMBL2537196 | 0.79 | MEN1 (0.58) | OPRD1KCNH2HRH3MEN1KMT2A | |
| SCHEMBL2315253 | 0.79 | MEN1 (0.58) | OPRD1KCNH2HRH3MEN1KMT2A | |
| SCHEMBL4146000 | 0.79 | MEN1 (0.58) | OPRD1KCNH2HRH3MEN1KMT2A | |
| SCHEMBL4096152 | 0.77 | CYP2D6 (0.56) | OPRD1HRH3MEN1KMT2AOPRL1 | |
| SCHEMBL4099767 | 0.77 | CYP2D6 (0.56) | OPRD1HRH3MEN1KMT2AOPRL1 | |
| SCHEMBL13724342 | 0.77 | CYP2D6 (0.56) | OPRD1HRH3MEN1KMT2AOPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | PANACOS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| WO-2008134036-A1 | ALPHA-SUBSTITUTED ARYLMETHYL PIPERAZINE PYRAZOLO[1,5-α]PYRIMIDINE AMIDE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215778-A1 | Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives | THPO, DPYD, TPMT | OPRD1 623/4885KCNA5 1703/4885KCNH2 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.